Share price · TEVA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TEVA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Jul 2026+9.6%
- 29 Apr 2026+11.9%
- 4 Feb 2026-3.6%
Nothing announced by TEVA that day or the session before.
Share of unusual movement by asset
For each asset, the share of TEVA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(13 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
| Approved | Glucocorticoid receptorSmall molecule | Asthma | |
| Approved | Myelin basic protein-mimetic immunomodulationPeptide | Multiple Sclerosis | |
| Approved | CGRP ligandMonoclonal antibody | Migraine | |
| Approved | Dopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Small molecule | Schizophrenia | |
| Approved | MAO-BSmall molecule | Parkinson's Disease | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
| Approved | CD20Monoclonal antibody | Rheumatoid ArthritisNon-Hodgkin LymphomaChronic Lymphocytic Leukemia | |
| Approved | GABA transporter (uptake carrier)Small molecule | Epilepsy Focal Onset Seizures | |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
| Phase 3 | Alpha-2 adrenergic receptor (agonist)Small molecule | SchizophreniaBipolar DisorderAlzheimer's Disease Alzheimer's Disease Agitation | |
| Phase 3 | TL1AMonoclonal antibody | Inflammatory Bowel DiseaseHidradenitis Suppurativa Ulcerative Colitis, Crohn's Disease | |
| Phase 1 | alpha-synuclein oligomersSmall molecule | Parkinson's Disease |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (19)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $4.4B | $297M | $4.1B | —$241M operating cash flow | report ↗ |
View 18 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $4.1B | $970M | $3.7B | $576M$411M operating cash flow | report ↗ |
| 2026-Q1 | $4.0B | $222M | $3.7B | — | report ↗ |
| 2025-Q4 | $4.7B | $267M | $3.6B | — | report ↗ |
| 2025-Q3 | $4.5B | $256M | $2.2B | — | report ↗ |
| 2025-Q2 | $4.2B | $244M | $2.2B | — | report ↗ |
| 2025-Q1 | $3.9B | $247M | $1.7B | — | report ↗ |
| 2024-Q4 | $4.2B | $248M | $3.3B | — | report ↗ |
| 2024-Q3 | $4.3B | $240M | $3.3B | — | report ↗ |
| 2024-Q2 | $4.2B | $269M | $2.3B | — | report ↗ |
| 2024-Q1 | $3.8B | $242M | $3.0B | $139M-$124M operating cash flow | report ↗ |
| 2023-Q3 | $3.9B | $253M | $2.3B | —$5.0M operating cash flow | report ↗ |
| 2023-Q2 | $3.9B | $240M | $2.7B | $863M$324M operating cash flow | report ↗ |
| 2023-Q1 | $3.7B | $234M | $2.2B | $205M-$145M operating cash flow | report ↗ |
| 2022-Q4 | — | — | $2.8B | $1.3B$973M operating cash flow | report ↗ |
| 2022-Q3 | $3.6B | $175M | $2.3B | —$543M operating cash flow | report ↗ |
| 2022-Q2 | $3.8B | $228M | $2.1B | $232M$123M operating cash flow | report ↗ |
| 2022-Q1 | $3.7B | $225M | $2.3B | $955M-$49M operating cash flow | report ↗ |
| 2021-Q3 | $3.9B | $222M | $2.0B | —$529M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $17.3B | $1.0B | $3.6B | — | report ↗ |
Teva reported FY2025 revenue of $17,258M, up 4.3% YoY, with R&D spend of $1,013M, up 1.5% YoY. Cash and equivalents stood at $3,556M, and the company recorded net income of $1,410M.
The 2025 results included a $500M development milestone received in the fourth quarter upon initiation of Phase 3 studies for duvakitug (anti-TL1A). During the year, Teva issued senior notes totaling $700M, €1,000M, and $500M, repaid several series of senior notes at maturity, and extinguished additional notes through a cash tender offer. It also entered into a $500M notional fixed-to-fixed cross-currency interest rate swap to hedge USD-denominated debt.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 64 sales ($124.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-15 | Bergwerk Dov · Interim Chief Legal Officer | Option exercise | 8,370 | — | — | Form 4 |
| 2026-11-15 | Bergwerk Dov · Interim Chief Legal Officer | Option exercise (derivative) | 8,370 | — | — | Form 4 |
| 2026-11-12 | Sabag Mark · See "Remarks" | Option exercise | 44,710 | $34.90 | $1.6M | Form 4 |
| 2026-11-12 | Sabag Mark · See "Remarks" | Open-market sale | 44,710 | $44.14 | $2.0M | Form 4 |
| 2026-11-12 | Sabag Mark · See "Remarks" | Option exercise (derivative) | 44,710 | — | — | Form 4 |
| 2026-11-11 | Daniell Richard · EVP, Europe Commercial | Option exercise | 20,003 | $34.70 | $694K | Form 4 |
| 2026-11-11 | Daniell Richard · EVP, Europe Commercial | Open-market sale | 20,003 | $42.80 | $856K | Form 4 |
| 2026-11-11 | Daniell Richard · EVP, Europe Commercial | Option exercise (derivative) | 20,003 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 647 reporting institutions held 673.8M shares ($16.9B, 57.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 65,136,464 | $2.0B |
| 2 | Phoenix Financial Ltd. | 42,777,414 | $1.3B |
| 3 | MENORA MIVTACHIM HOLDINGS LTD. | 39,626,383 | $1.2B |
| 4 | WCM INVESTMENT MANAGEMENT, LLC | 40,820,600 | $1.2B |
| 5 | Migdal Insurance & Financial Holdings Ltd. | 37,902,212 | $1.1B |
| 6 | FMR LLC | 33,132,795 | $998.0M |
| 7 | Lingotto Investment Management LLP | 27,770,857 | $836.5M |
| 8 | STATE STREET CORP | 17,790,020 | $535.8M |
| 9 | Rubric Capital Management LP | 15,250,000 | $459.3M |
| 10 | Altshuler Shaham Ltd | 11,463,621 | $334.6M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 10,564,988 | $316.3M |
| 12 | Capital World Investors | 8,833,566 | $266.1M |
| 13 | NORTHERN TRUST CORP | 7,635,688 | $230.0M |
| 14 | MORGAN STANLEY | 7,426,253 | $223.7M |
| 15 | WELLINGTON MANAGEMENT GROUP LLP | 7,251,828 | $218.4M |